2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies and the  2017 focused update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol.

Please also review the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA (Multisociety) Guideline on the Management of Blood Cholesterol (aka 2018 Cholesterol Management Guideline) before engaging in this week's discussion.

• https://www.jacc.org/doi/pdf/10.1016/j.jacc.2018.11.003
• https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Guidelines/2018/Guidelines-Made-Simple-Tool-2018-Cholesterol.pdf

A 54-year-old South Asian man with diabetes mellitus, HTN, dyslipidemia, and gastroesophageal reflux disease (GERD). He is a current smoker. His current medications include lisinopril 20 mg/day, amlodipine 10 mg/day, pravastatin 40 mg/day, and omeprazole 20 mg/day. Fasting laboratory results show glucose 109 mg/dL, TC 197 mg/dL, LDL-C 128 mg/dL, HDL-C 37 mg/dL, and TG 166 mg/dL. His non-HDL is 160 mg/dL. His systolic blood pressure is 130 mmHg and the PCE (pooled Cohort Equation) estimates his 10 year risk of ASCVD to be 26.8%.

• Based on currently available guidelines and patient specific criteria given in the case, what is your plan for this patient? Be sure to include: 1- Lifestyle modifications 2- Drug, dose, rationale and monitoring 3- what to do in the event there is complaints of myopathy 4 - Patient education.

Answer rating: 100% (QA)

Based on the patients profile and the guidelines provided heres a plan for managing this patient Lifestyle Modifications Smoking Cessation Since the patient is a current smoker smoking cessation is a ... View the full answer